At a joint meeting of the European Parliament’s Committees on Public Health and Industry on Thursday 19 March, the European Commissioner for Health, Olivér Várhelyi, stressed the central importance of investment in the biotechnology sector in Europe. In his view, Europe suffers from a chronic lack of risk-taking in this area, despite growing twice as fast as the rest of the economy. European investors, including institutional investors, remain insufficiently committed to this strategic...